Revelation Biosciences (REVB) EBIT (2021 - 2026)
Revelation Biosciences (REVB) posted quarterly EBIT of -$2.6 million for Q4 2025, down 46.62% year-over-year from -$4.8 million in Q4 2024, and down 32.35% quarter-over-quarter from -$1.9 million in Q3 2025.
Revelation Biosciences (REVB) EBIT (2021 - 2026) Analysis & Trends
Revelation Biosciences (REVB) has reported EBIT for 5 consecutive years, with -$2.6 million the latest figure, recorded in Q4 2025.
- In Q4 2025, EBIT fell 46.62% year-over-year to -$2.6 million; the TTM figure through Dec 2025 stood at -$9.1 million (down 13.74% YoY), while the FY2025 annual figure was -$9.1 million, down 13.74% from the prior year.
- EBIT retreated to -$2.6 million in Q4 2025 per REVB's latest filing, from -$1.9 million in the prior quarter.
- Across five years, EBIT topped out at -$1.2 million in Q3 2022 and bottomed at -$6.6 million in Q1 2022.
- Historically, EBIT has averaged -$2.4 million across 5 years, with a median of -$2.2 million in 2023.
- Annual changes were most pronounced in 2022 — EBIT slumped 152.57% — and 2023, when it surged 75.41%.
- Revelation Biosciences' EBIT stood at -$3.9 million in 2021, then surged by 68.41% to -$1.2 million in 2022, then plunged by 90.91% to -$2.3 million in 2023, then advanced by 24.59% to -$1.8 million in 2024, then slumped by 46.62% to -$2.6 million in 2025.
- Business Quant data shows REVB's EBIT at -$2.6 million in Q4 2025, -$1.9 million in Q3 2025, and -$2.5 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.25 Bn | 131.40 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 86.04 Bn | 78.05 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 65.43 Bn | 60.25 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 58.26 Bn | 53.13 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 42.10 Bn | 37.00 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.61 Bn | 28.31 Bn | 992.69 Mn | 231.44 Mn |
| 7 | BioNTech SE | 28.03 Bn | 9.63 Bn | 668.28 Mn | -375.75 Mn |
| 8 | Insmed | 27.49 Bn | 26.33 Bn | 358.27 Mn | -1.55 Mn |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - | 133.12 Mn |
| 10 | Revelation Biosciences | 4.13 Mn | -7.37 Mn | - | -3.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -3.66 Mn |
| Dec 31, 2025 | -2.57 Mn |
| Sep 30, 2025 | -1.94 Mn |
| Jun 30, 2025 | -2.46 Mn |
| Mar 31, 2025 | -2.09 Mn |
| Dec 31, 2024 | -1.75 Mn |
| Sep 30, 2024 | -1.80 Mn |
| Jun 30, 2024 | -2.52 Mn |
| Mar 31, 2024 | -1.90 Mn |
| Dec 31, 2023 | -2.33 Mn |
| Sep 30, 2023 | -2.78 Mn |
| Jun 30, 2023 | -1.93 Mn |
| Mar 31, 2023 | -1.62 Mn |
| Dec 31, 2022 | -1.22 Mn |
| Sep 30, 2022 | -1.20 Mn |
| Jun 30, 2022 | -1.86 Mn |
| Mar 31, 2022 | -6.59 Mn |
| Dec 31, 2021 | -3.86 Mn |
| Sep 30, 2021 | -3.04 Mn |
| Jun 30, 2021 | -2.44 Mn |